Ranked #5,678 of 8,699 institutional investors
Pivotal bioVenture Partners Investment Advisor LLC
San Francisco, CA
$233M
US stock portfolio at live prices · today −$5.2M (−2.18%)
Live prices, last trade 12:52 PM ET
- Value at quarter end (Q3 2026)
- $252M
- Change from Q2 2026
- −$56.0M (−18.20%)
- Positions
- 13 · 2 new, 1 sold out
- Filed
- Nov 13, 2026
Not counted in the ranking: none$15.5M of holdings we could not match to a US listing are included at their reported quarter-end value.
Holdings
Q3 2026 13F, live pricesPCVX 34.4%ARQT 11.6%AVLN 10.7%TRVI 10.0%EVMN 5.83%
| Stock | Shares | Value, live | % of portfolio | vs Q2 2026 |
|---|---|---|---|---|
| PCVX Vaxcyte, Inc. | 1,425,470 | $80.2M | 34.4% | Unchanged |
| ARQT Arcutis Biotherapeutics, Inc. | 1,008,174 | $26.9M | 11.6% | Reduced −20% |
| AVLN Avalyn Pharma Inc. | 866,792 | $24.9M | 10.7% | Reduced −10% |
| TRVI Trevi Therapeutics, Inc. | 1,742,672 | $23.4M | 10.0% | Unchanged |
| EVMN Evommune Inc | 1,926,943 | $13.6M | 5.83% | Unchanged |
| IMNM Immunome, Inc. | 732,512 | $11.7M | 5.03% | Unchanged |
| OBX Obsidian Therapeutics, Inc. | 860,343 | $10.2M | 4.40% | New |
| BRVE Braveheart Bio, Inc. | 317,351 | $6.4M | 2.73% | New |
| ZBIO Zenas BioPharma, Inc. | 233,176 | $5.9M | 2.54% | Reduced −52% |
| RLYB Rallybio Corporation | 300,579 | $4.6M | 1.96% | Unchanged |
| MPLT MapLight Therapeutics, Inc. | 611,446 | $3.7M | 1.61% | Unchanged |
| AVTX Avalo Therapeutics, Inc. | 434,033 | $2.9M | 1.26% | Unchanged |
| BIOA BioAge Labs, Inc. | 653,374 | $2.9M | 1.23% | Unchanged |
Sold out in Q3 2026
| Stock | Shares held at Q2 2026 | Worth today |
|---|---|---|
| RXRX Recursion Pharmaceuticals, Inc. | 595,518 | $1.5M |